Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
Background: [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients. Methods: We retrospectively analyzed clinical, renal, and salivary scintigraphy data and salivary...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/5/315 |
| _version_ | 1797514888926461952 |
|---|---|
| author | Tim Wollenweber Lucia Zisser Elisabeth Kretschmer-Chott Michael Weber Bernhard Grubmüller Gero Kramer Shahrokh F. Shariat Markus Mitterhauser Stefan Schmitl Chrysoula Vraka Alexander R. Haug Marcus Hacker Markus Hartenbach Sazan Rasul |
| author_facet | Tim Wollenweber Lucia Zisser Elisabeth Kretschmer-Chott Michael Weber Bernhard Grubmüller Gero Kramer Shahrokh F. Shariat Markus Mitterhauser Stefan Schmitl Chrysoula Vraka Alexander R. Haug Marcus Hacker Markus Hartenbach Sazan Rasul |
| author_sort | Tim Wollenweber |
| collection | DOAJ |
| description | Background: [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients. Methods: We retrospectively analyzed clinical, renal, and salivary scintigraphy data and salivary [<sup>68</sup>Ga]Ga-PSMA-11 ligand PET scan measures such as metabolic volume and SUVmax values of 27 mCRPC men (mean age 71 ± 7 years) before and 4 weeks after receiving three cycles of PSMA-RLT every 4 weeks. Twenty-two patients additionally obtained renal and salivary scintigraphy prior to each cycle. A one-way ANOVA, post-hoc Scheffé test and Cochran’s Q test were applied to assess organ toxicity. Results: In total, 54 PSMA PET scans, 98 kidney, and 98 salivary scintigraphy results were evaluated. There were no significant differences for the ejection fraction, peak time, and residual activity after 5 min for both parotid and submandibular glands prior to each cycle and 4 weeks after the last cycle. Similarly, no significant differences in serum creatinine and renal scintigraphy parameters were observed prior to each cycle and 4 weeks after the last treatment. Despite there being no changes in the metabolic volume of both submandibular glands, SUVmax values dropped significantly (<i>p</i> < 0.05). Conclusion: Results evidenced no alterations in renal function and only minimal impairment of salivary function of mCRPC patients who acquired an intense PSMA-RLT regimen every 4 weeks. |
| first_indexed | 2024-03-10T06:37:55Z |
| format | Article |
| id | doaj.art-c303b018d7954348a2dd2aa516b46bd5 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T06:37:55Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-c303b018d7954348a2dd2aa516b46bd52023-11-22T17:54:50ZengMDPI AGCurrent Oncology1198-00521718-77292021-09-012853692370410.3390/curroncol28050315Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate CancerTim Wollenweber0Lucia Zisser1Elisabeth Kretschmer-Chott2Michael Weber3Bernhard Grubmüller4Gero Kramer5Shahrokh F. Shariat6Markus Mitterhauser7Stefan Schmitl8Chrysoula Vraka9Alexander R. Haug10Marcus Hacker11Markus Hartenbach12Sazan Rasul13Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Biomedical Imaging and Image-guided Therapy, Division of General Radiology, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Urology, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Urology, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Urology, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, AustriaBackground: [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients. Methods: We retrospectively analyzed clinical, renal, and salivary scintigraphy data and salivary [<sup>68</sup>Ga]Ga-PSMA-11 ligand PET scan measures such as metabolic volume and SUVmax values of 27 mCRPC men (mean age 71 ± 7 years) before and 4 weeks after receiving three cycles of PSMA-RLT every 4 weeks. Twenty-two patients additionally obtained renal and salivary scintigraphy prior to each cycle. A one-way ANOVA, post-hoc Scheffé test and Cochran’s Q test were applied to assess organ toxicity. Results: In total, 54 PSMA PET scans, 98 kidney, and 98 salivary scintigraphy results were evaluated. There were no significant differences for the ejection fraction, peak time, and residual activity after 5 min for both parotid and submandibular glands prior to each cycle and 4 weeks after the last cycle. Similarly, no significant differences in serum creatinine and renal scintigraphy parameters were observed prior to each cycle and 4 weeks after the last treatment. Despite there being no changes in the metabolic volume of both submandibular glands, SUVmax values dropped significantly (<i>p</i> < 0.05). Conclusion: Results evidenced no alterations in renal function and only minimal impairment of salivary function of mCRPC patients who acquired an intense PSMA-RLT regimen every 4 weeks.https://www.mdpi.com/1718-7729/28/5/315PSMAprostate cancermCRPCrenal scintigraphysalivary scintigraphy |
| spellingShingle | Tim Wollenweber Lucia Zisser Elisabeth Kretschmer-Chott Michael Weber Bernhard Grubmüller Gero Kramer Shahrokh F. Shariat Markus Mitterhauser Stefan Schmitl Chrysoula Vraka Alexander R. Haug Marcus Hacker Markus Hartenbach Sazan Rasul Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer Current Oncology PSMA prostate cancer mCRPC renal scintigraphy salivary scintigraphy |
| title | Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer |
| title_full | Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer |
| title_fullStr | Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer |
| title_full_unstemmed | Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer |
| title_short | Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer |
| title_sort | renal and salivary gland functions after three cycles of psma 617 therapy every four weeks in patients with metastatic castration resistant prostate cancer |
| topic | PSMA prostate cancer mCRPC renal scintigraphy salivary scintigraphy |
| url | https://www.mdpi.com/1718-7729/28/5/315 |
| work_keys_str_mv | AT timwollenweber renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT luciazisser renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT elisabethkretschmerchott renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT michaelweber renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT bernhardgrubmuller renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT gerokramer renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT shahrokhfshariat renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT markusmitterhauser renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT stefanschmitl renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT chrysoulavraka renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT alexanderrhaug renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT marcushacker renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT markushartenbach renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer AT sazanrasul renalandsalivaryglandfunctionsafterthreecyclesofpsma617therapyeveryfourweeksinpatientswithmetastaticcastrationresistantprostatecancer |